PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investors

April 10, 2024 7:45 AM EDT | Source: PharmaCielo Ltd. /NOT FOR DISTRIBUTION…

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in…

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024 This is a Designated News Release.…

IGC Pharma Reports Third Quarter Fiscal 2024 Results

POTOMAC, Md., February 17, 2024–(BUSINESS WIRE)–IGC Pharma, Inc. (“IGC” or the “Company”)…

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company’s…

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

License allows PharmAla to drive revenue and growth while remaining true to…

Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials 

Any clinical trial program relies heavily on its administrators, advisors, and designers.…